Transcriptional up-regulation of SOD1 by CEBPD: A potential target for cisplatin resistant human urothelial carcinoma cells

Biochemical Pharmacology

Volumn 80, Issue 3, 2010, Pages 325-334

  Hour, Tzyh Chyuan ^a   Lai, Yan Liang ^a   Kuan, Ching I ^a   Chou, Chen Kung ^b   Wang, Ju Ming ^c   Tu, Huang Yao ^a   Hu, Huei Ting ^a   Lin, Chang Shen ^a   Wu, Wen Jeng ^d   Pu, Yeong Shiau ^e   Sterneck, Esta ^f   Huang, A Mei ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

C EBP transcription factor; Cisplatin drug resistance; SOD inhibitor; Superoxide dismutase; Urothelial carcinoma

Indexed keywords

ARSENIC TRIOXIDE; CCAAT ENHANCER BINDING PROTEIN DELTA; CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; GEMCITABINE; PACLITAXEL; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UPREGULATION;

APOPTOSIS; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CISPLATIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; SUPEROXIDE DISMUTASE; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; UROLOGIC NEOPLASMS;

EID: 77953359913     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.007     Document Type: Article

References (65)

1. Bischoff C.J., Clark P.E. Bladder cancer. Curr Opin Oncol 2009, 21:272-277.
2. Kaufman D.S. Challenges in the treatment of bladder cancer. Ann Oncol 2006, 17(Suppl 5):v106-v112.
3. Bellmunt J., Albiol S., Suarez C., Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 2009, 69:211-222.
4. Zamble D.B., Lippard S.J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995, 20:435-439.
5. Sedletska Y., Giraud-Panis M.J., Malinge J.M. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem 2005, 5:251-265.
6. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-320.
7. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
8. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23.
9. Miyajima A., Nakashima J., Yoshioka K., Tachibana M., Tazaki H., Murai M. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 1997, 76:206-210.
10. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009, 8:579-591.
11. Chirino Y.I., Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009, 61:223-242.
12. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
13. Torigoe T., Izumi H., Ishiguchi H., Yoshida Y., Tanabe M., Yoshida T., et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005, 5:15-27.
14. Koh M.Y., Spivak-Kroizman T.R., Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin Cancer Res 2009, 15:5945-5946.
15. Corn P.G., El-Deiry W.S. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther 2007, 6.
16. Yun Z., Maecker H.L., Johnson R.S., Giaccia A.J. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2002, 2:331-341.
17. Tang Y., Pacary E., Freret T., Divoux D., Petit E., Schumann-Bard P., et al. Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: identification of potential neuroprotective candidates for stroke. Neurobiol Dis 2006, 21:18-28.
18. Johnson P.F. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci 2005, 118:2545-2555.
19. Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol 2007, 17:318-324.
20. Ramji D.P., Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 2002, 365:561-575.
21. Hendricks-Taylor L.R., Darlington G.J. Inhibition of cell proliferation by C/EBP alpha occurs in many cell types, does not require the presence of p53 or Rb, and is not affected by large T-antigen. Nucleic Acids Res 1995, 23:4726-4733.
22. Schuster M.B., Porse B.T. C/EBPalpha: a tumour suppressor in multiple tissues?. Biochim Biophys Acta 2006, 1766:88-103.
23. Sebastian T., Johnson P.F. Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta. Cell Cycle 2006, 5:953-957.
24. Alam T., An M.R., Papaconstantinou J. Differential expression of three C/EBP isoforms in multiple tissues during the acute phase response. J Biol Chem 1992, 267:5021-5024.
25. Huang A.M., Rudelius M., Sharan S., McAllister J.M., Raffeld M., Christenson L.K., et al. The Cebpd (C/EBPdelta) gene is induced by luteinizing hormones in ovarian theca and interstitial cells but is not essential for mouse ovary function. PLoS ONE 2007, 2:e1334.
26. Lekstrom-Himes J., Xanthopoulos K.G. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem 1998, 273:28545-28548.
27. Huang A.M., Montagna C., Sharan S., Ni Y., Ried T., Sterneck E. Loss of CCAAT/enhancer binding protein delta promotes chromosomal instability. Oncogene 2004, 23:1549-1557.
28. Thangaraju M., Rudelius M., Bierie B., Raffeld M., Sharan S., Hennighausen L., et al. C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development 2005, 132:4675-4685.
29. Porter D., Lahti-Domenici J., Keshaviah A., Bae Y.K., Argani P., Marks J., et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003, 1:362-375.
30. Sanford D.C., DeWille J.W. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate 2005, 63:143-154.
31. Gery S., Tanosaki S., Hofmann W.K., Koppel A., Koeffler H.P. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene 2005, 24:1589-1597.
32. Ko C.Y., Hsu H.C., Shen M.R., Chang W.C., Wang J.M. Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem 2008, 283:30919-30932.
33. Tang D., Sivko G.S., DeWille J.W. Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors. Breast Cancer Res Treat 2006, 95:161-170.
34. Thangaraju M., Ananth S., Martin P.M., Roon P., Smith S.B., Sterneck E., et al. c/ebpdelta Null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J Biol Chem 2006, 281:26769-26773.
35. Wang J.M., Ko C.Y., Chen L.C., Wang W.L., Chang W.C. Functional role of NF-IL6beta and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene. Nucleic Acids Res 2006, 34:217-231.
36. Yu H.J., Tsai T.C., Hsieh T.S., Chiu T.Y. Characterization of a newly established human bladder carcinoma cell line, NTUB1. J Formosan Med Assoc 1992, 91:608-613.
37. Hour T.C., Chen J., Huang C.Y., Guan J.Y., Lu S.H., Hsieh C.Y., et al. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines. Anticancer Res 2000, 20:3221-3225.
38. Hour T.C., Huang C.Y., Lin C.C., Chen J., Guan J.Y., Lee J.M., et al. Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide. Anticancer Drugs 2004, 15:779-785.
39. Chou T.C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976, 59:253-276.
40. Pu Y.S., Hour T.C., Chen J., Huang C.Y., Guan J.Y., Lu S.H. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 2002, 13:293-300.
41. Rojo A.I., Salinas M., Martin D., Perona R., Cuadrado A. Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. J Neurosci 2004, 24:7324-7334.
42. Lai P.H., Wang W.L., Ko C.Y., Lee Y.C., Yang W.M., Shen T.W., et al. HDAC1/HDAC3 modulates PPARG2 transcription through the sumoylated CEBPD in hepatic lipogenesis. Biochim Biophys Acta 2008, 1783:1803-1814.
43. Miller M., Shuman J.D., Sebastian T., Dauter Z., Johnson P.F. Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha. J Biol Chem 2003, 278:15178-15184.
44. Boonstra J., Post J.A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004, 337:1-13.
45. Heinemeyer T., Wingender E., Reuter I., Hermjakob H., Kel A.E., Kel O.V., et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998, 26:362-367.
46. Brown D.P., Chin-Sinex H., Nie B., Mendonca M.S., Wang M. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol 2009, 63:723-730.
47. Sun L., Hui A.M., Su Q., Vortmeyer A., Kotliarov Y., Pastorino S., et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006, 9:287-300.
48. Covell D.G., Wallqvist A., Rabow A.A., Thanki N. Molecular classification of cancer: unsupervised self-organizing map analysis of gene expression microarray data. Mol Cancer Ther 2003, 2:317-332.
49. Matsumoto H., Wada T., Fukunaga K., Yoshihiro S., Matsuyama H., Naito K. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol 2004, 34:124-130.
50. Wilson L.A., Yamamoto H., Singh G. Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther 2004, 3:823-832.
51. Clerkin J.S., Naughton R., Quiney C., Cotter T.G. Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett 2008, 266:30-36.
52. Byun S.S., Kim S.W., Choi H., Lee C., Lee E. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int 2005, 95:1086-1090.
53. Wang J., Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 2008, 7:1875-1884.
54. Powis G., Kirkpatrick D.L. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 2007, 7:392-397.
55. Blander G., de Oliveira R.M., Conboy C.M., Haigis M., Guarente L. Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J Biol Chem 2003, 278:38966-38969.
56. McCord J.M., Edeas M.A. SOD, oxidative stress and human pathologies: a brief history and a future vision. Biomed Pharmacother 2005, 59:139-142.
57. Park E.Y., Rho H.M. The transcriptional activation of the human copper/zinc superoxide dismutase gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin through two different regulator sites, the antioxidant responsive element and xenobiotic responsive element. Mol Cell Biochem 2002, 240:47-55.
58. Yoo H.Y., Chang M.S., Rho H.M. The activation of the rat copper/zinc superoxide dismutase gene by hydrogen peroxide through the hydrogen peroxide-responsive element and by paraquat and heat shock through the same heat shock element. J Biol Chem 1999, 274:23887-23892.
59. Yoo H.Y., Chang M.S., Rho H.M. Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. Gene 1999, 234:87-91.
60. Carter C.D., Kitchen L.E., Au W.C., Babic C.M., Basrai M.A. Loss of SOD1 and LYS7 sensitizes Saccharomyces cerevisiae to hydroxyurea and DNA damage agents and downregulates MEC1 pathway effectors. Mol Cell Biol 2005, 25:10273-10285.
61. Lee H.C., Kim D.W., Jung K.Y., Park I.C., Park M.J., Kim M.S., et al. Increased expression of antioxidant enzymes in radioresistant variant from U251 human glioblastoma cell line. Int J Mol Med 2004, 13:883-887.
62. Nishikawa M., Nagatomi H., Nishijima M., Ohira G., Chang B.J., Sato E., et al. Targeting superoxide dismutase to renal proximal tubule cells inhibits nephrotoxicity of cisplatin and increases the survival of cancer-bearing mice. Cancer Lett 2001, 171:133-138.
63. Lowndes S.A., Sheldon H.V., Cai S., Taylor J.M., Harris A.L. Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. Microvasc Res 2009, 77:314-326.
64. Donate F., Juarez J.C., Burnett M.E., Manuia M.M., Guan X., Shaw D.E., et al. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer 2008, 98:776-783.
65. Sorenson J.R., Wangila G.W. Co-treatment with copper compounds dramatically decreases toxicities observed with cisplatin cancer therapy and the anticancer efficacy of some copper chelates supports the conclusion that copper chelate therapy may be markedly more effective and less toxic than cisplatin therapy. Curr Med Chem 2007, 14:1499-1503.